NCT03153202View on ClinicalTrials.gov

Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 14, 2017

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions

Chronic Lymphocytic LeukemiaMantle Cell Lymphoma

Interventions

DRUG

Ibrutinib

once daily oral intake ibrutinib

DRUG

Pembrolizumab

200mg IV pembrolizumab on Day 1 of each cycle

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Joshua Brody

OTHER

NCT03153202 - Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | Biotech Hunter | Biotech Hunter